ABBV-CLS-628

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameABBV-CLS-628
Drug Alias NameABBV-CLS-628
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionPappalysin-1 inhibitors
TargetsPappalysin-1
Therapy Area/IndicationsPolycystic Kidney, Autosomal DominantKidney Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPortugal +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesCalico Life Sciences Llc
Inactive CompaniesN/A
Active IndicationsPolycystic Kidney, Autosomal DominantKidney Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A